UPDATE: HTG, John Wayne Cancer Institute Partner on Melanoma Assays | GenomeWeb

This article has been updated with comments from HTG's CEO and additional background information.

NEW YORK (GenomeWeb News) – HTG Molecular Diagnostics today said that it has partnered with the John Wayne Cancer Institute to commercialize melanoma assays based on molecular signatures identified through a research collaboration between the partners.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.